39 results
Search Results
2. Exploring the effectiveness of a regional nurse practitioner led, long‐acting injectable buprenorphine‐based model of care for opioid use disorder.
- Author
-
Strike, Teresa, D'Angelo‐Kemp, Dante, and Searby, Adam
- Subjects
- *
DRUG addiction , *NARCOTICS , *NEEDLE exchange programs , *PSYCHIATRIC nursing , *AUDITING , *STATISTICS , *INJECTIONS , *EVALUATION of human services programs , *NURSE administrators , *BUPRENORPHINE , *RURAL conditions , *AMBULANCES , *DRUG overdose , *RETROSPECTIVE studies , *REGRESSION analysis , *OUTPATIENT medical care management , *PEARSON correlation (Statistics) , *CONTROLLED release preparations , *COMMUNITY mental health personnel , *STATISTICAL models , *DATA analysis , *DATA analysis software , *PAIN management , *OPIOID abuse , *HEROIN - Abstract
The introduction of long‐acting injectable buprenorphine preparations for opioid use disorder has been widely heralded as a breakthrough treatment, with several studies indicating positive results when using these medications. In many locations, nurse practitioners prescribe, administer, and monitor long‐acting injectable preparations. The objective of this paper is to explore whether a reduction in dispensed needles and syringes is attributable to increased nurse practitioner prescribing of LAIB. We used a retrospective audit of needles dispensed through the health service needle and syringe program vending machine, and individuals treated with long‐acting injectable buprenorphine by the nurse practitioner led model. In addition, we examined potential factors that may influence changes in the number of needles dispensed. Linear regression found that each individual with opioid dependence treated with long‐acting injectable buprenorphine was associated with 90 fewer needles dispensed each month (p < 0.001). The nurse practitioner led model of care for individuals with opioid dependence appears to have influenced the number of needles dispensed at the needle and syringe program. Although all confounding factors could not be discounted entirely, such as substance availability, affordability, and individuals obtaining injecting equipment elsewhere, our research indicates that a nurse practitioner led model of treating individuals with opioid use disorder influenced needle and syringe dispensing in the study setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Study: Counterfeits/fentanyl making drug use more deadly for adolescents.
- Author
-
Knopf, Alison
- Subjects
- *
HEALTH policy , *OCCUPATIONAL roles , *SAFETY , *NARCOTICS , *DISEASE clusters , *SUBSTANCE abuse , *DRUG overdose , *SOCIAL media , *FENTANYL , *CURRICULUM , *PARENTING , *HEALTH literacy , *SCHOOLS , *POLICY sciences , *DRUG counterfeiting , *DOSAGE forms of drugs , *PATIENT safety , *ADOLESCENCE - Abstract
As Scott E. Hadland, M.D., senior author of a dramatic paper published last week in the New England Journal of Medicine puts it, drug use among adolescents is not getting more common — it's at its lowest in almost 50 years. But it's getting more deadly, due to fentanyl. In "The Overdose Crisis among U.S. Adolescents," by Hadland and lead author Joseph Friedman, Ph.D., the problem is laid out clearly: After guns and car crashes, overdose (OD) deaths are now the third leading cause of death among adolescents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Emotion regulation in substance use disorders: a systematic review and meta‐analysis.
- Author
-
Stellern, Jordan, Xiao, Ke Bin, Grennell, Erin, Sanches, Marcos, Gowin, Joshua L., and Sloan, Matthew E.
- Subjects
- *
SUBSTANCE abuse diagnosis , *SUBSTANCE abuse & psychology , *ONLINE information services , *PSYCHOLOGY information storage & retrieval systems , *NARCOTICS , *META-analysis , *MEDICAL information storage & retrieval systems , *CONFIDENCE intervals , *ALCOHOLISM , *SYSTEMATIC reviews , *CROSS-sectional method , *METHAMPHETAMINE , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *EMOTION regulation , *MEDLINE , *DATA analysis software , *PSYCHOLOGICAL resilience , *COMPULSIVE behavior - Abstract
Background and aims: The ability to regulate emotions effectively has been associated with resilience to psychopathology. Individuals with substance use disorders (SUDs) have been shown to have higher levels of negative emotionality, with some evidence suggesting impairment in emotion regulation compared with individuals without SUDs. However, no previous attempt has been made to systematically review the literature to assess the magnitude of this difference. We aimed to assess the association between SUD diagnosis and emotion regulation as measured by the Difficulties in Emotion Regulation Scale (DERS) and Emotion Regulation Questionnaire (ERQ) through a systematic review and meta‐analysis of existing findings. Methods: The systematic review was conducted using PubMed, PsycINFO and Embase. We examined cross‐sectional studies that compared a SUD group with a control group and measured emotion regulation using the DERS or the ERQ. The primary analysis focused on papers using the DERS, as this was the predominant instrument in the literature. Results: Twenty‐two studies met our primary analysis criteria, representing 1936 individuals with a SUD and 1567 controls. Individuals with SUDs relative to controls had significantly greater DERS scores, with a mean difference of 21.44 [95% confidence interval (CI) = 16.49–26.40, P < 0.001] and Hedges' g = 1.05 (95% CI = 0.86–1.24, P < 0.001). The difference was robust, remaining significant after removing outliers and studies with high risk of bias. Individuals with SUDs demonstrated poorer emotion regulation on each subscale of the DERS, with the largest deficits in the Strategies and Impulse subscales. The ERQ analysis revealed greater use of expressive suppression in those with SUDs relative to controls (Hedges' g = 0.76, 95% CI = 0.25–1.28, P = 0.004). Conclusions: People with substance use disorders appear to have greater difficulties in emotion regulation than people without substance use disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. AATOD white paper details how OTPs and buprenorphine providers can collaborate.
- Subjects
- *
BUPRENORPHINE , *DRUG addiction , *INTERPROFESSIONAL relations , *NARCOTICS , *PHYSICIANS , *SUBSTANCE abuse treatment - Abstract
A new report from the American Association for the Treatment of Opioid Dependence (AATOD) focuses on how opioid treatment programs (OTPs) can collaborate with other health care providers, including office-based buprenorphine prescribers, on closing the treatment gap for opioid use disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. A dose‐finding design for dual‐agent trials with patient‐specific doses for one agent with application to an opiate detoxification trial.
- Author
-
Mozgunov, Pavel, Cro, Suzie, Lingford‐Hughes, Anne, Paterson, Louise M., and Jaki, Thomas
- Subjects
- *
NARCOTICS , *CLINICAL trials - Abstract
There is a growing interest in early phase dose‐finding clinical trials studying combinations of several treatments. While the majority of dose finding designs for such setting were proposed for oncology trials, the corresponding designs are also essential in other therapeutic areas. Furthermore, there is increased recognition of recommending the patient‐specific doses/combinations, rather than a single target one that would be recommended to all patients in later phases regardless of their characteristics. In this paper, we propose a dose‐finding design for a dual‐agent combination trial motivated by an opiate detoxification trial. The distinguishing feature of the trial is that the (continuous) dose of one compound is defined externally by the clinicians and is individual for every patient. The objective of the trial is to define the dosing function that for each patient would recommend the optimal dosage of the second compound. Via a simulation study, we have found that the proposed design results in high accuracy of individual dose recommendation and is robust to the model misspecification and assumptions on the distribution of externally defined doses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. The effects of whey proteins, their peptides and amino acids on vascular function.
- Author
-
Price, Drew, Jackson, Kim G., Lovegrove, Julie A., and Givens, David Ian
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *BLOOD pressure , *HYPERTENSION , *NARCOTICS , *CARDIOVASCULAR system physiology , *CARDIOVASCULAR diseases , *OXIDATIVE stress , *WHEY proteins , *AMINO acids , *NITRIC oxide , *PEPTIDES - Abstract
Cardiovascular diseases (CVD) are a significant and growing burden on global health services, and it is now accepted that impairment of vascular function represents a major preliminary step in the development of CVD. There is considerable interest in identifying both causal factors of impaired vascular function, as well as related nutritional factors that may lower the risk of developing CVD, and food‐derived bioactive peptides and amino acids have emerged as one such area. Dairy foods contain two groups of proteins, whey proteins and caseins, which represent a rich source of bioactive peptides that are released during food processing and/or digestion. These peptides have a number of physiological activities including the potential to reduce blood pressure. Research, including acute and longer‐term randomised controlled trials, animal models and in vitro models has demonstrated the potential impact of dairy proteins on vascular function. The purpose of this paper is to narratively review the evidence, primarily from randomised controlled trials, examining the effects of whey proteins, their peptides and amino acids on vascular function and related issues including blood pressure. In addition, it will explore the potential underlying mechanisms responsible for these effects. It concludes that there is increasing evidence that whey proteins, and notably the bioactive peptides and amino acids released during their digestion, can have beneficial effects on aspects of vascular function and thus contribute to CVD risk reduction. It also highlights a number of beneficial effects of whey proteins including those on blood pressure, arterial stiffness, nitric oxide production and inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Data on COVID payments' effect on overdose don't match the hype.
- Subjects
- *
SUICIDE risk factors , *NARCOTICS , *CAUSES of death , *COVID-19 , *DRUG overdose , *ANALGESICS , *MEDICAL care costs , *SOCIOECONOMIC factors , *RISK assessment , *DISEASE complications - Abstract
A newly released study suggests that economic impact payments to individuals during the pandemic might have contributed to a surge in opioid overdose deaths, but the results are being portrayed to the public as having a much more dramatic impact. While the study paper from researchers at Bowling Green State University clearly states that the results don't indicate that the payments caused the rise in deaths, language in a news release from the Ohio Attorney General's Office implies a cause‐and‐effect relationship. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Prevalence of Problematic Use of Opioids in Patients with Chronic Noncancer Pain: A Systematic Review with Meta‐analysis.
- Author
-
Jantarada, Cláudia, Silva, Catarina, and Guimarães‐Pereira, Luís
- Subjects
- *
NARCOTICS , *CHRONIC pain , *DRUG addiction , *SUBSTANCE abuse , *META-analysis , *ANALGESICS , *SYSTEMATIC reviews , *DISEASE prevalence , *TUMORS , *MEDLINE , *PAIN management - Abstract
Background and Objective: Opioid prescription for chronic noncancer pain is associated with problematic use. We aimed to review and summarize the evidence on the prevalence of problematic use of opioids in adults with chronic noncancer pain and investigate whether the prevalence rates were changing over time. Databases and Data Treatment: A systematic review of the literature was undertaken following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. We systematically searched the literature in the electronic databases MEDLINE, SCOPUS, and Web of Science and studies with adult participants with chronic noncancer pain using opioids with indication of one or more of the following terms about problematic opioid use: abuse, misuse, addiction, dependence, problematic use, and aberrant behavior/use were eligible for data extraction. Meta‐analysis was performed to estimate the pooled prevalence rates using a random‐effects model, and subanalysis was conducted. Results: Our search identified a total of 784 potentially relevant studies. After a thorough evaluation, 19 papers, mostly from the United States, were included in our qualitative and quantitative synthesis. The majority of the data came from speciality pain clinics. The estimated prevalence of problematic use of opioids in adults with chronic noncancer pain was 36.3% (95% confidence interval: 27.4 to 45.2%; I2 = 99.64%). Problematic opioid use was mostly identified using the questionnaire method. Thirteen studies (68%) presented a low risk of bias. Conclusions: Our study presents an alarming estimate regarding the prevalence of problematic use of opioids among patients with noncancer pain. These results deserve special attention from health care professionals and health authorities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. The interaction of neonatal abstinence syndrome and opioid use disorder treatment availability for women insured by medicaid.
- Author
-
Reising, Virginia A., Horne, Ashley, and Bennett, Amanda C.
- Subjects
- *
SUBSTANCE abuse treatment , *NARCOTICS , *NEONATAL abstinence syndrome , *SUBSTANCE abuse , *HEALTH services accessibility , *ACQUISITION of data methodology , *ANALGESICS , *RURAL conditions , *POPULATION geography , *PREGNANT women , *DISEASE incidence , *DESCRIPTIVE statistics , *MEDICAL records , *MEDICAID , *DISCHARGE planning , *PREGNANCY - Abstract
Objective: This paper will discuss the process of mapping opioid use disorder (OUD) treatment resources for pregnant women and discuss the intersection between treatment resources and rates of neonatal abstinence syndrome (NAS). Design: A resource manual was developed through a systematic process with stakeholders across Illinois. Resources were mapped by county and overlaid with county rates of NAS, using hospital discharge data. Results: Across Illinois, 89 treatment resources were identified for pregnant women insured by Medicaid. Resources were concentrated in 36% of Illinois' counties. Counties with limited treatment resources generally had high rates of NAS. Sixty‐six percent of NAS cases among rural Illinois residents had no OUD treatment resources in their county. Rural counties had less access to medication‐assisted treatment (MAT), the standard of care for treatment of OUD, compared with other counties across the state. Conclusions: Efforts to increase OUD treatment options for pregnant women insured by Medicaid should concentrate on geographic areas with limited access and high need. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Review article: Rapid review of the emergency department‐initiated buprenorphine for opioid use disorder.
- Author
-
Salter, Helen, Hutton, Jennie, Cantwell, Kate, Dietze, Paul, Higgs, Peter, Straub, Adam, Zordan, Rachel, and Lloyd‐Jones, Martyn
- Subjects
- *
BUPRENORPHINE , *CINAHL database , *HOSPITAL emergency services , *MEDICAL databases , *INFORMATION storage & retrieval systems , *MEDICAL information storage & retrieval systems , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *NARCOTICS , *PATIENT compliance , *SUBSTANCE abuse , *PATIENT participation , *SYSTEMATIC reviews , *TREATMENT effectiveness , *EVALUATION - Abstract
Opioid‐related harms have been increasing in Australia over the last 5 years. Patients with opioid use disorder are over‐represented in ED presentations. Opioid agonist treatment is the most effective community‐based treatment. Buprenorphine is considered the safest of these treatments to use in the ED setting. This rapid review investigated the effectiveness of initiating buprenorphine in the ED setting. Medline, Embase, Emcare, PSYCinfo, CINAHL and Cochrane Central Register of Controlled Trials databases were searched. Randomised and non‐randomised studies published in peer‐reviewed journals that involved the initiation of buprenorphine in the ED setting were considered eligible. The search revealed 350 articles of which 11 were included in the review; three articles representing two randomised controlled trials (RCTs) and eight observational studies. Data were extracted from included papers and risk of bias assessed on the RCTs. One well‐conducted RCT showed that buprenorphine initiated in the ED does improve treatment engagement up to 2 months after an ED visit. Eight observational studies, one with a comparator group reported positive results for this intervention. There is strong evidence that clinicians should consider commencing buprenorphine in the ED for patients with opioid use disorder when combined with a direct and supported referral or 'warm handover' to community care. Further implementation studies and investigation of long‐acting injectable buprenorphine treatment are required. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Report: 1115 waivers provide funds but don't ensure effective SUD care.
- Author
-
Enos, Gary
- Subjects
- *
MEDICAID law , *SUBSTANCE abuse treatment , *SUBSTANCE abuse , *MEDICAL quality control , *NARCOTICS , *HEALTH services accessibility , *REPORT writing , *ANALGESICS , *HEALTH insurance reimbursement , *QUALITY assurance , *GOVERNMENT aid , *MEDICAL needs assessment - Abstract
The primary manner by which states have been using Medicaid to expand access to substance use disorder (SUD) treatment may actually be making it more difficult for individuals to receive the services most appropriate to their needs, a newly released paper suggests. Moreover, this preferred strategy in many cases violates the law, authors with the National Health Law Program contend. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Prominent researchers argue against more of the same in treatment funding.
- Author
-
Enos, Gary
- Subjects
- *
CONFLICT (Psychology) , *HEALTH services accessibility , *MEDICAL quality control , *HEALTH policy , *NARCOTICS , *PRACTICAL politics , *SUBSTANCE abuse treatment , *GOVERNMENT aid , *HEALTH insurance reimbursement , *TREATMENT programs - Abstract
An over‐reliance on federal block grants and "one‐off" funding initiatives has left the addiction treatment system under‐resourced to respond to an addiction crisis that stands to be at least as deadly as COVID‐19 during the span of the Biden administration, a trio of prominent researchers argue in a newly released policy paper. The authors suggest that the new administration and Congress should prioritize efforts to build on what they consider the most impactful developments in improving access and quality in addiction treatment, such as Medicaid expansion and parity mandates. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Incorporating methods and findings from neuroscience to better understand placebo and nocebo effects in sport.
- Author
-
Beedie, Christopher, Benedetti, Fabrizio, Barbiani, Diletta, Camerone, Eleanora, Lindheimer, Jacob, and Roelands, Bart
- Subjects
- *
AUTONOMIC nervous system physiology , *ANALGESICS , *ATHLETIC ability , *BASAL ganglia , *CAFFEINE , *DOPAMINE , *FATIGUE (Physiology) , *FRONTAL lobe , *MOTIVATION (Psychology) , *PSYCHOLOGY of movement , *NARCOTICS , *NEUROBIOLOGY , *NEUROSCIENCES , *PLACEBOS , *PSYCHOPHYSIOLOGY , *PAIN measurement , *NEURAL pathways - Abstract
Placebo and nocebo effects are a factor in sports performance. However, the majority of published studies in sport science are descriptive and speculative regarding mechanisms. It is therefore not unreasonable for the sceptic to argue that placebo and nocebo effects in sport are illusory, and might be better explained by variations in phenomena such as motivation. It is likely that, in sport at least, placebo and nocebo effects will remain in this empirical grey area until researchers provide stronger mechanistic evidence. Recent research in neuroscience has identified a number of consistent, discrete and interacting neurobiological and physiological pathways associated with placebo and nocebo effects, with many studies reporting data of potential interest to sport scientists, for example relating to pain, fatigue and motor control. Findings suggest that placebos and nocebos result in activity of the opioid, endocannabinoid and dopamine neurotransmitter systems, brain regions including the motor cortex and striatum, and measureable effects on the autonomic nervous system. Many studies have demonstrated that placebo and nocebo effects associated with a treatment, for example an inert treatment presented as an analgesic or stimulant, exhibit mechanisms similar or identical to the verum or true treatment. Such findings suggest the possibility of a wide range of distinct placebo and nocebo mechanisms that might influence sports performance. In the present paper, we present some of the findings from neuroscience. Focussing on fatigue as an outcome and caffeine as vehicle, we propose three approaches that researchers in sport might incorporate in their studies in order to better elucidate mechanisms of placebo/nocebo effects on performance. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. The becoming‐methadone‐body: on the onto‐politics of health intervention translations.
- Author
-
Rhodes, Tim, Azbel, Lyuba, Lancaster, Kari, and Meyer, Jaimie
- Subjects
- *
HIV prevention , *METHADONE treatment programs , *CORRECTIONAL institutions , *DRUG addiction , *HEROIN , *PRISONERS , *NARCOTICS , *PRACTICAL politics - Abstract
In this paper, we reflect on health intervention translations as matters of their implementation practices. Our case is methadone treatment, an intervention promoted globally for treating opioid dependence and preventing HIV among people who inject drugs. Tracing methadone's translations in high‐security prisons in the Kyrgyz Republic, we notice the multiple methadones made possible, what these afford, and the onto‐political effects they make. We work with the idea of the 'becoming‐methadone‐body' to trace the making‐up of methadone treatment and its effects as an intra‐action of human and nonhuman substances and bodies. Methadone's embodied effects flow beyond the mere psycho‐activity of substances incorporating individual bodies, to material highs and lows incorporating the governing practices of prisoner society. The methadone‐in‐practice of prisoner society is altogether different to that imagined as being in translation as an intervention of HIV prevention and opioid treatment, and has material agency as a practice of societal governance. Heroin also emerges as an actor in these relations. Our analysis troubles practices of 'evidence‐based' intervention and 'implementation science' in the health field, by arguing for a move towards 'evidence‐making' intervention approaches. Noticing the onto‐politics of health intervention translations invites speculation on how intervening might be done differently. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. The impact of expanded Medicaid eligibility on access to naloxone.
- Author
-
Frank, Richard G. and Fry, Carrie E.
- Subjects
- *
CONFIDENCE intervals , *DRUG overdose , *HEALTH care reform , *RESEARCH methodology , *MEDICAID , *HEALTH policy , *MEDICAL prescriptions , *NARCOTICS , *POVERTY , *THERAPEUTICS - Abstract
Background and Aims: Federal, state and local US governments have sought interventions to reduce deaths due to opioid overdoses by increasing the availability of naloxone. The Affordable Care Act (ACA) expanded Medicaid coverage to low‐income, childless adults, potentially giving this group financial access to naloxone. The aims of this paper are: (1) to describe the changes in the amount of Medicaid‐covered naloxone used between 2009 and 2016 and (2) to quantify the differential change in the amount of dispensed naloxone between states that expanded their Medicaid programs and states that did not. Design A quasi‐experimental approach based on states' ongoing choice to expand their Medicaid program to all adults with incomes between 100 and 138% of the federal poverty line (FPL), starting in 2014. As of 2018, 37 states had expanded and 14 states had not. Estimation of the policy impact relies on a difference‐in‐difference method. Setting: US state Medicaid programs. Participants and measurements: Data are from the Medicaid Drug Rebate Program and include all dispensed prescriptions of naloxone through the Medicaid program. State/quarters with fewer than 10 prescriptions are suppressed; n = 1632. Findings Prior to Medicaid expansion, the number of Medicaid‐covered naloxone prescriptions was very similar in expansion and non‐expansion states. On average, states that expanded Medicaid had 78.2 (95% confidence interval = 16.0–140.3, P = 0.02) more prescriptions per year for naloxone compared with states that did not expand Medicaid coverage, a nearly 10 increase over the pre‐expansion years. Medicaid expansion contributed to this growth in Medicaid‐covered naloxone more than other state‐level naloxone policies. Conclusions: Medicaid accounts for approximately a quarter of naloxone sales. Medicaid expansion generated 8.3% of the growth in naloxone units from 2009 to 2016, holding other factors constant. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
- Author
-
Lipton, Richard B., Munjal, Sagar, Buse, Dawn C., Alam, Aftab, Fanning, Kristina M., Reed, Michael L., Schwedt, Todd J., and Dodick, David W.
- Subjects
- *
MENTAL illness risk factors , *SLEEP disorders , *ALLODYNIA , *BARBITURATES , *BLACK people , *CARDIOVASCULAR diseases , *MEDICAL needs assessment , *MEDICAL prescriptions , *MIGRAINE , *NARCOTICS , *NOSOLOGY , *ORAL drug administration , *PATIENT satisfaction , *SELF-evaluation , *SKIN diseases , *SUBSTANCE abuse , *SURVEYS , *WHITE people , *PAIN management , *COMORBIDITY , *DISEASE relapse , *DISABILITIES , *TREATMENT effectiveness , *CROSS-sectional method , *SEVERITY of illness index , *DISEASE duration , *EVALUATION , *DISEASE risk factors ,MIGRAINE complications - Abstract
Objectives: To characterize unmet treatment needs in a sample of Migraine in America Symptoms and Treatment (MAST) Study participants using oral, acute prescription migraine medications. Background: The MAST Study is a 2017 study of US adults with migraine that profiles current treatment patterns and identifies and quantifies unmet treatment needs. Methods: Cross‐sectional data from an online survey of US adults meeting ICHD‐3 beta criteria for migraine. For inclusion in this paper, respondents self‐reported a history of 3 or more monthly headache days (MHDs) in the past 3 months and at least 1 MHD in the past 30 days, and current use of orally administered acute prescription medication for headache. Three domains of unmet need were identified: inadequate treatment response (ie, inadequate 2‐hour pain freedom, recurrence within 24 hours of initial relief), demanding attack characteristics (rapid onset of attack, headache associated with sleep), and unique patient characteristics (opioid or barbiturate overuse, cardiovascular comorbidity). Sociodemographics, oral medication use, and coexisting conditions and symptoms (ie, level of treatment optimization, psychological symptoms, attack‐related cutaneous allodynia, and migraine symptom severity) were assessed for each domain and by the number of unmet need domains. Results: Overall, 15,133 respondents met inclusion criteria, 26.0% (3930/15,133) reported current use of oral acute prescription medication to treat headache. Eligible participants had a mean age of 45.0 years, 73.6% [2892/3930] were women and 81.1% [3186/3930]) were White. A total of 95.8% (3765/3930) of respondents had at least 1 unmet acute treatment need; 89.5% (3516/3930) reported demanding attack characteristics, 74.1% (2912/3930) reported inadequate treatment response, and 16.1% (634/3930) presented with unique patient characteristics. Common areas of unmet need were rapid headache onset (65.3% [2567/3930]), moderate to severe disability (55.6% [2187/3930]), inadequate 2‐hours pain freedom (49.0% [1892/3930]), and headache recurrence within 24 hours (38.0% [1493/3930]). An increasing number of unmet treatment need domains was associated with worsening psychological symptoms, attack‐related cutaneous allodynia and migraine symptom severity. Conclusion: Nearly all MAST Study respondents using acute oral prescription medications for migraine reported at least 1 unmet treatment need. As unmet needs increased, so did coexisting conditions and symptom severity. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Commentary on Burns et al: MOUD saves lives, especially after 60 days, and the longer the better.
- Subjects
- *
METHADONE treatment programs , *NARCOTICS , *SUBSTANCE abuse , *BUPRENORPHINE , *DRUG overdose , *TREATMENT duration , *TREATMENT effectiveness - Abstract
The article comments on a paper by M. Burns and colleagues on the effectiveness of methadone or buprenorphine in the treatment of opioid use disorder (OUD). Topics mentioned include the assessment of the impact of immortal time bias on patients' survival, the reduction in hazards of overdose after continuous medication, and the need to improve equality in clinical outcomes for racial minorities with medications for OUD.
- Published
- 2022
- Full Text
- View/download PDF
19. Koob: Understanding negative reinforcers of opioids could uncover new treatments.
- Author
-
Enos, Gary
- Subjects
- *
SUBSTANCE abuse treatment , *TREATMENT of drug withdrawal symptoms , *PSYCHOLOGICAL adaptation , *ANALGESICS , *COGNITIVE therapy , *NARCOTICS , *REINFORCEMENT (Psychology) , *PSYCHOLOGICAL stress , *STRESS management , *SUBSTANCE abuse , *DISEASE complications - Abstract
A new research paper on the neurobiology of opioid addiction is replete with complex terms, such as the pivotal "hyperkatifeia" (coined about a decade ago to describe an increase in the intensity of the negative emotional signs of drug withdrawal). But the primary takeaway message from the report's author, National Institute on Alcohol Abuse and Alcoholism (NIAAA) Director George Koob, M.D., is much more accessible and direct. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Illicit fentanyls in the opioid street market: desired or imposed?
- Author
-
Mars, Sarah G., Rosenblum, Daniel, and Ciccarone, Daniel
- Subjects
- *
DRUGS , *DRUGS of abuse , *FENTANYL , *HEALTH services accessibility , *HEROIN , *MARKETING , *NARCOTICS , *HEALTH literacy , *PSYCHOLOGY of drug abusers - Abstract
Background: Illicitly manufactured fentanyl and its analogues are appearing in countries throughout the world, often disguised as heroin or counterfeit prescription pills, with resulting high overdose mortality. Possible explanations for this phenomenon include reduced costs and risks to heroin suppliers, heroin shortages, user preferences for a strong, fast‐acting opioid and the emergence of Dark Web cryptomarkets. This paper addresses these potential causes and asks three questions: (1) can users identify fentanyl; (2) do users desire fentanyl; and (3) if users want fentanyl, can they express this demand in a way that influences the supply? Argument/analysis: Existing evidence, while limited, suggests that some users can identify fentanyl, although not reliably, and some desire it, but because fentanyl is frequently marketed deceptively as other drugs, users lack information and choice to express demand effectively. Even when aware of fentanyl's presence, drug users may lack fentanyl‐free alternatives. Cryptomarkets, while difficult to quantify, appear to offer buyers greater information and competition than offline markets. However, access barriers and patterns of fentanyl‐related health consequences make cryptomarkets unlikely sources of user influence on the fentanyl supply. Market condition data indicate heroin supply shocks and shortages prior to the introduction of fentanyl in the United States and parts of Europe, but the much lower production cost of fentanyl compared with heroin may be a more significant factor Conclusion: Current evidence points to a supply‐led addition of fentanyl to the drug market in response to heroin supply shocks and shortages, changing prescription opioid availability and/or reduced costs and risks to suppliers. Current drug users in affected regions of the United States, Canada and Europe appear largely to lack both concrete knowledge of fentanyl's presence in the drugs they buy and access to fentanyl‐free alternatives. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Reducing opioid‐related harms: practice in Australian hospitals in 2018.
- Subjects
- *
SUBSTANCE abuse prevention , *SUBSTANCE abuse risk factors , *INAPPROPRIATE prescribing (Medicine) , *ANALGESICS , *COMMUNITY health workers , *COUNSELING , *DRUG prescribing , *HEALTH facilities , *HEALTH services accessibility , *HOSPITAL pharmacies , *HOSPITAL admission & discharge , *MEDICAL care , *NARCOTICS , *PATIENTS , *PATIENT safety , *GENERAL practitioners , *PUBLIC hospitals , *SURVEYS , *PAIN management , *PHYSICIAN practice patterns , *PRIVATE sector , *OCCUPATIONAL roles , *HARM reduction , *DISCHARGE planning , *MEDICATION therapy management , *PHARMACISTS , *STAKEHOLDER analysis , *PREVENTION , *ATTITUDE (Psychology) - Abstract
The SHPA thanks its Opioid Advocacy Working Group for their contributions to this paper and the original report: Jane Booth, Thuy Bui, Annabel Calder, Christine Coorey, Michael Dooley, Paul Firman, Kerry Fitzsimons, Marisa Hodgkinson, Jacinta Johnson, Margaret Jordan, Miriam Lawrence, Daniel Lim, Duncan McKenzie, Peter Samios, Benita Suckling, Penelope Tuffin and Jason Waddell, supported by Johanna de Wever, Jerry Yik, Courtney Munro and Maria Khokhar from the SHPA secretariat. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Extended‐release injectable naltrexone for opioid use disorder: a systematic review.
- Author
-
Jarvis, Brantley P., Holtyn, August F., Subramaniam, Shrinidhi, Tompkins, D. Andrew, Oga, Emmanuel A., Bigelow, George E., and Silverman, Kenneth
- Subjects
- *
BUPRENORPHINE , *CONFIDENCE intervals , *CONTROLLED release preparations , *DRUG utilization , *DRUGS , *DRUG administration , *DRUG overdose , *HELP-seeking behavior , *MEDICAL records , *MEDLINE , *NALTREXONE , *NARCOTICS , *ONLINE information services , *PATIENT compliance , *SUBSTANCE abuse , *SYSTEMATIC reviews , *TERMINATION of treatment , *TREATMENT effectiveness - Abstract
Abstract: Aims: To review systematically the published literature on extended‐release naltrexone (XR‐NTX, Vivitrol®), marketed as a once‐per‐month injection product to treat opioid use disorder. We addressed the following questions: (1) how successful is induction on XR‐NTX; (2) what are adherence rates to XR‐NTX; and (3) does XR‐NTX decrease opioid use? Factors associated with these outcomes as well as overdose rates were examined. Methods: We searched PubMed and used Google Scholar for forward citation searches of peer‐reviewed papers from January 2006 to June 2017. Studies that included individuals seeking treatment for opioid use disorder who were offered XR‐NTX were included. Results: We identified and included 34 studies. Pooled estimates showed that XR‐NTX induction success was lower in studies that included individuals that required opioid detoxification [62.6%, 95% confidence interval (CI) = 54.5–70.0%] compared with studies that included individuals already detoxified from opioids (85.0%, 95% CI = 78.0–90.1%); 44.2% (95% CI = 33.1–55.9%) of individuals took all scheduled injections of XR‐NTX, which were usually six or fewer. Adherence was higher in prospective investigational studies (i.e. studies conducted in a research context according to a study protocol) compared to retrospective studies of medical records taken from routine care (6‐month rates: 46.7%, 95% CI = 34.5–59.2% versus 10.5%, 95% CI = 4.6–22.4%, respectively). Compared with referral to treatment, XR‐NTX reduced opioid use in adults under criminal justice supervision and when administered to inmates before release. XR‐NTX reduced opioid use compared with placebo in Russian adults, but this effect was confounded by differential retention between study groups. XR‐NTX showed similar efficacy to buprenorphine when randomization occurred after detoxification, but was inferior to buprenorphine when randomization occurred prior to detoxification. Conclusions: Many individuals intending to start extended‐release naltrexone (XR‐NTX) do not and most who do start XR‐NTX discontinue treatment prematurely, two factors that limit its clinical utility significantly. XR‐NTX appears to decrease opioid use but there are few experimental demonstrations of this effect. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. The future of the international drug control system and national drug prohibitions.
- Author
-
Hall, Wayne
- Subjects
- *
DRUG control , *CANNABIS (Genus) , *MARIJUANA laws , *INTERNATIONAL cooperation on drug control , *NARCOTIC laws , *CRITICISM , *DRUGS of abuse , *HALLUCINOGENIC drugs , *HEALTH promotion , *INTERNATIONAL relations , *HEALTH policy , *NARCOTICS , *PSYCHIATRIC drugs , *SUBSTANCE abuse , *MANUFACTURING industries , *HARM reduction - Abstract
Abstract: A major impediment to any nation abandoning the policy of drug prohibition has been the fact that international drug treaties to which the majority of United Nations (UN) member states are signatory prohibit the non‐medical use of amphetamines, cannabis, cocaine and heroin. The future of these treaties is now uncertain because of decisions by Uruguay, eight US states and Canada to legalize cannabis use. This paper: (1) provides a brief account of the international drug control treaties; (2) outlines the major criticisms of the treaties; (3) analyses critically proposals for treaty reform; and (4) provides a personal view on policies that nation states could adopt to minimize the harms from the use of cannabis, party drugs and hallucinogens, opioids, stimulants and new psychoactive substances. It is argued that: a major risk of cannabis legalization in the United States is promotion of heavy use and increased harm by a weakly regulated industry; some cautious national experiments with the regulation of party drugs and hallucinogens would be informative; a strong case remains for prohibiting the nonmedical use of opioids while mitigating the adverse effects that this policy has on opioid‐dependent people; stimulant legalization will probably increase problem use but prohibition is difficult to enforce, highlighting the urgency of finding better ways to reduce demand for these drugs and respond to problem users; and that it is unclear what the best approach is to reducing possible harms that may arise from the use of new psychoactive substances. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Remote sampling mass spectrometry for dry samples: Sheath‐flow probe electrospray ionization (PESI) using a gel‐loading tip inserted with an acupuncture needle.
- Author
-
Usmanov, Dilshadbek T., Ashurov, Khatam B., Ninomiya, Satoshi, Hiraoka, Kenzo, Wada, Hiroshi, Nakano, Hiroshi, Matsumura, Masaya, Sanada‐Morimura, Sachiyo, and Nonami, Hiroshi
- Subjects
- *
MASS spectrometry , *ELECTROSPRAY ionization mass spectrometry , *ACUPUNCTURE , *SOLVENTS , *NARCOTICS , *ACUPUNCTURE needles - Abstract
Rationale: Probe electrospray ionization (PESI) is only applicable to liquid or wet samples. In this study, a sheath‐flow PESI method for remote sampling mass spectrometry that can be applied to dry samples was developed. Methods: An acupuncture needle (0.12 mm outer diameter, 700 nm tip diameter) was inserted into a gel‐loading tip with a 0.1 mm protrusion out of the tip. Analytes were extracted by filling the latter tip with solvent and softly touching the sample surface for a short time (<1 s). A high voltage was applied to the acupuncture needle, and mass spectra of analytes were obtained by self‐aspirating electrospray. Results: Dry samples, such as lines of ballpoint pen ink on paper, pharmaceutical tablets, instant coffee, brown rice, and narcotics, gave strong ion signals. The sample carryover was negligible. The sequential electrospray was observed to be similar to conventional PESI. The limits of detection (LODs) for morphine and rhodamine B were found to be of the order of picograms. Conclusions: Because of its simplicity and versatility, sheath‐flow PESI is a promising technique for on‐site and nondestructive profile analysis of dry samples with bulky and complicated shapes, with a spatial resolution of ~0.3 mm. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance.
- Author
-
Murray, Donna E., Durazzo, Timothy C., Schmidt, Thomas P., Murray, Troy A., Abé, Christoph, Guydish, Joseph, and Meyerhoff, Dieter J.
- Subjects
- *
CEREBRAL circulation , *NARCOTICS , *DRUG addiction , *SUBSTANCE-induced disorders , *NEUROPSYCHOLOGY - Abstract
Neuroimaging of opiate-dependent individuals indicates both altered brain structure and function. Magnetic resonance-based arterial spin labeling has been used to measure noninvasively cerebral blood flow (i.e. perfusion) in alcohol, tobacco and stimulant dependence; only one arterial spin labeling paper in opiate-dependent individuals demonstrated frontal and parietal perfusion deficits. Additional research on regional brain perfusion in opiate dependence and its relationship to cognition and self-regulation (impulsivity, risk taking and decision making) may inform treatment approaches for opiate-dependent individuals. Continuous arterial spin labeling magnetic resonance imaging at 4 T and neuropsychological measures assessed absolute brain perfusion levels, cognition and self-regulation in 18 cigarette smoking opiate-dependent individuals (sODI) stable on buprenorphine maintenance therapy. The sODI were compared with 20 abstinent smoking alcohol-dependent individuals (a substance-dependent control group), 35 smoking controls and 29 nonsmoking controls. sODI had lower perfusion in several cortical and subcortical regions including regions within the brain reward/executive oversight system compared with smoking alcohol-dependent individuals and nonsmoking controls. Perfusion was increased in anterior cingulate cortex and globus pallidus of sODI. Compared with all other groups, sODI had greater age-related declines in perfusion in most brain reward/executive oversight system and some other regions. In sODI, lower regional perfusion related to greater substance use, higher impulsivity and weaker visuospatial skills. Overall, sODI showed cortical and subcortical hypoperfusion and hyperperfusion. Relating to neuropsychological performance and substance use quantities, the frontal perfusion alterations are clinically relevant and constitute potential targets for pharmacological and cognitive-based therapeutic interventions to improve treatment outcome in opiate dependence. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Safer and more appropriate opioid prescribing: a large healthcare system's comprehensive approach.
- Author
-
Losby, Jan L., Hyatt, Joel D., Kanter, Michael H., Baldwin, Grant, and Matsuoka, Denis
- Subjects
- *
NARCOTICS , *BENZODIAZEPINES , *COMBINATION drug therapy , *HEALTH facilities , *MEDICAL care , *MEDICAL prescriptions , *TRANQUILIZING drugs , *TREATMENT effectiveness , *RETROSPECTIVE studies , *ACYCLIC acids , *ELECTRONIC health records - Abstract
Rationale, aims, and objectives The United States is in the midst of a public health epidemic with more than 40 people dying each day from prescription opioid overdoses. Health care systems are taking steps to address the opioid overdose epidemic by implementing policy and practice interventions to mitigate the risks of long-term opioid therapy. Kaiser Permanente Southern California launched a comprehensive initiative to transform the way that chronic pain is viewed and treated. Kaiser Permanente Southern California created prescribing and dispensing policies, monitoring and follow-up processes, and clinical coordination through electronic health record integration. The purpose of this paper is to describe the implementation of these interventions and assess the impact of this set of interventions on opioid prescribing. Method The study used a retrospective pre-post evaluation design to track outcomes before and after the intervention. Kaiser Permanente Southern California members age 18 and older excluding cancer, hospice, and palliative care patients and this sub-population of 3 203 880 was approximately 75% of all Kaiser Permanente Southern California members. All data are from Kaiser Permanente's pharmacy data systems and electronic health record collected on a rolling basis as interventions were implemented from January 2010 to December 2015. Results There were reductions in all tracked outcomes: a 30% reduction in prescribing opioids at high doses; a 98% reduction in the number of prescriptions with quantities greater than 200 pills; a 90% decrease in the combination of an opioid prescription with benzodiazepines and carisoprodol; a 72% reduction in the prescribing of Long Acting/Extended Release opioids; and a 95% reduction in prescriptions of brand name opioid-acetaminophen products. In addition, methadone prescribing did not increase during this period. Conclusions This study adds promising results that a comprehensive system-level strategy has the ability to positively affect opioid prescribing. The basic components of the intervention are generalizable and applicable to other health care settings. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Cascade of Care approach to opioid crisis would incentivize MAT: Study.
- Author
-
Enos, Gary
- Subjects
- *
SUBSTANCE abuse prevention , *MORTALITY prevention , *SUBSTANCE abuse diagnosis , *ACCREDITATION , *ANALGESICS , *CONVALESCENCE , *HEALTH services accessibility , *NARCOTICS , *PUBLIC health , *SUBSTANCE abuse , *STANDARDS - Abstract
Adoption of a unified public health framework for the treatment of opioid use disorders (OUDs) would encourage more continuity of care and use of evidence‐based medication treatments to combat the crisis, suggest researchers with Columbia University and the New York State Psychiatric Institute. Moreover, they state in a newly published paper, the "Cascade of Care" framework they seek to advance could be used to improve accreditation standards they believe do not sufficiently address providers that do not use methadone, buprenorphine or injectable naltrexone in their treatment of opioid addiction. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Treatment field takes a step toward civil commitment.
- Author
-
Knopf, Alison
- Subjects
- *
SUBSTANCE abuse treatment , *SUBSTANCE abuse , *INSTITUTIONAL care , *MEDICAL ethics , *MEDICAL records , *NARCOTICS , *PRIVACY , *SELF-management (Psychology) , *RULES , *TREATMENT programs , *INVOLUNTARY hospitalization , *PATIENT autonomy , *LAW - Abstract
The article talks about the concept of civil commitment for substance use disorders (SUDs), discussing a research paper released by Hazelden Betty Ford Foundation. Topics discussed include the views of some people that addiction is a disease and its treatment should not be coerced; a paper by the U.S. National Institute on Drug Abuse (NIDA) on it; and the benefits of involuntary commitment laws for substance use disorders.
- Published
- 2017
- Full Text
- View/download PDF
29. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.
- Author
-
Krebs, Emanuel, Urada, Darren, Evans, Elizabeth, Huang, David, Hser, Yih‐Ing, and Nosyk, Bohdan
- Subjects
- *
OPIOID abuse , *DRUG abuse prevention , *DRUG abuse prevention -- Finance , *CRIME statistics , *ECONOMIC impact of crime , *MEDICATION abuse , *PREVENTION , *SUBSTANCE abuse treatment , *CRIME , *SUBSTANCE abuse , *CHI-squared test , *CONFIDENCE intervals , *CRIMINALS , *DRUGS , *FISHER exact test , *NARCOTICS , *PROBABILITY theory , *RESEARCH funding , *GOVERNMENT aid , *DETOXIFICATION (Alternative medicine) , *TREATMENT programs , *PRE-tests & post-tests , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *MANN Whitney U Test - Abstract
Background and aims Treatment for opioid use disorders (OUD) reduces the risk of mortality and infectious disease transmission; however, opportunities to quantify the potential economic benefits of associated decreases in drug-related crime are scarce. This paper aimed to estimate the costs of crime during and after periods of engagement in publicly funded treatment for OUD to compare total costs of crime during a hypothetical 6-month period following initiation of opioid agonist treatment (OAT) versus detoxification. Design Retrospective, administrative data-based cohort study with comprehensive information on drug treatment and criminal justice systems interactions. Setting Publicly funded drug treatment facilities in California, USA (2006-10). Participants A total of 31 659 individuals admitted for the first time to treatment for OUD, and who were linked with criminal justice and mortality data, were followed during a median 2.3 years. Median age at first treatment admission was 32, 35.8% were women and 37.1% primarily used prescription opioids. Measurements Daily costs of crime (US$2014) were calculated from a societal perspective and were composed of the costs of policing, court, corrections and criminal victimization. We estimated the average marginal effect of treatment engagement in OAT or detoxification adjusting for potential fixed and time-varying confounders, including drug use and criminal justice system involvement prior to treatment initiation. Findings Daily costs of crime during treatment compared with after treatment were $126 lower for OAT [95% confidence interval (CI) = $116, $136] and $144 lower for detoxification (95% CI = $135, $154). Summing the costs of crime during and after treatment over a hypothetical 6-month period using the observed median durations of OAT (161 days) and detoxification (19 days), we estimated that enrolling an individual in OAT as opposed to detoxification would save $17 550 ($16 840, $18 383). Conclusions In publicly funded drug treatment facilities in California, USA, engagement in treatment for opioid use disorders is associated with lower costs of crime in the 6 months following initiation of treatment, and the economic benefits were far greater for individuals receiving time-unlimited treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Circumstances surrounding non-fatal opioid overdoses attended by ambulance services.
- Author
-
Madah‐Amiri, Desiree, Clausen, Thomas, Myrmel, Lars, Brattebø, Guttorm, Lobmaier, Philipp, Madah-Amiri, Desiree, and Brattebø, Guttorm
- Subjects
- *
OPIOIDS , *DRUG overdose , *EMERGENCY medical services , *DRUG abuse , *EMERGENCY medicine , *NALOXONE , *NARCOTIC antagonists , *AMBULANCES , *ANALGESICS , *NARCOTICS , *RETROSPECTIVE studies , *DIAGNOSIS , *THERAPEUTICS - Abstract
Introduction and Aims: Opioid overdose fatalities are a significant concern globally. Non-fatal overdoses have been described as a strong predictor for future overdoses, and are often attended by the ambulance services. This paper explores characteristics associated with non-fatal overdoses and aims to identify possible trends among these events in an urban area in Norway.Design and Methods: This is a retrospective analysis of non-fatal overdoses from Bergen ambulance services from 2012 to 2013. Demographic, temporal and geographic data were explored.Results: During the two years, 463 non-fatal opioid overdoses were attended by ambulance services. Ambulance call-outs occurred primarily during the late afternoon and evening hours of weekdays. Summer months had more overdoses than other seasons, with a peak in August. Overdoses were nearly twice as likely to occur in a public location in August (risk ratio 1.92, P = 0.042). Ambulance response times were more likely to be longer to private locations, and these victims were more likely to be treated and left at the scene. There was no difference in arrival time for drug-related and non-drug related dispatch.Discussion and Conclusions: The temporal patterns suggest that non-fatal overdoses occur during non-recreational time periods. The longer ambulance response time and disposition for private addresses indicate potential opportunities for peer interventions. Our analysis describes circumstances surrounding non-fatal overdoses and can be useful in guiding relevant, targeted prevention interventions. [Madah-Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P. Circumstances surrounding non-fatal opioid overdoses attended by ambulance services. Drug Alcohol Rev 2017;36:288-294]. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Managing opioid overdose in pregnancy with take‐home naloxone.
- Author
-
Blandthorn, Julie, Bowman, Ellen, Leung, Laura, Bonomo, Yvonne, and Dietze, Paul
- Subjects
- *
NALOXONE , *ANALGESICS , *DRUG overdose , *MEDICAL protocols , *NARCOTIC antagonists , *NARCOTICS , *PRENATAL care , *RESUSCITATION , *TREATMENT effectiveness , *PREGNANCY , *THERAPEUTICS - Abstract
Programs have recently been established in Australia and internationally to allow wider access to naloxone to people at risk of opioid overdose yet there are no guidelines relating to the administration of naloxone to pregnant women, particularly regarding dose requirements and resuscitative measures peculiar to pregnancy. This paper provides practical guidelines to health workers in relation to any complications that may arise during opioid overdose response (including the administration of naloxone) for pregnant women and the follow up required ensuring best possible outcomes for mother and baby. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine.
- Author
-
Pringsheim, Tamara, Davenport, William Jeptha, Marmura, Michael J., Schwedt, Todd J., and Silberstein, Stephen
- Subjects
- *
ANALGESICS , *ANTIEMETICS , *MIGRAINE , *NARCOTICS , *NONSTEROIDAL anti-inflammatory agents , *TRYPTAMINE , *DECISION making in clinical medicine , *DIHYDROERGOTAMINE , *PHARMACODYNAMICS - Abstract
The 'Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies' provides levels of evidence for medication efficacy for acute treatment of migraine. The goal of this companion paper is to provide guidance on how to choose between evidence-based treatment options, and, based on the clinical characteristics of the patient and their migraine attacks, to provide guidance on designing an individualized strategy for managing migraine attacks. The acute pharmacological treatments described in the American Headache Society evidence assessment can be divided into those initially taken by the patient during the headache phase of the migraine attack, those taken by the patient later in the attack when initial treatments fail, and those administered intravenously or intramuscularly in urgent care settings. Medications taken initially by patients in the headache phase include nonspecific analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, and dihydroergotamine (DHE). A stratified approach to treatment is advised, with the choice of medication based on the patient's treatment needs, taking into consideration the attack severity, presence of associated symptoms such as nausea and vomiting, and the degree of migraine-related disability. Individuals with migraine may find reassurance in having a 'back-up plan' in the event of an initial acute treatment failure. For those individuals who had a partial response to the initial acute treatment, a second dose might be indicated. When the initial treatment does not provide meaningful and sustained benefits, a treatment from a different medication class is typically chosen. Depending upon the initial treatment used, this might include NSAIDs, triptans, or DHE. Opioids or acetaminophen in combination with codeine or tramadol can be considered as part of the 'back-up plan,' provided they are used infrequently. When all patient administered treatments have failed and moderate to severe migraine symptoms remain, some individuals seek treatment in urgent care settings. The intravenous administration of antiemetics with or without an intravenous or intramuscular NSAID or DHE, or an intramuscular opioid can be considered. Patients with migraine should be encouraged to treat migraine pain early, and avoid overuse of medications. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids.
- Author
-
Peacock, Amy, Bruno, Raimondo, Cama, Elena, Kihas, Ivana, Larance, Briony, Lintzeris, Nick, Hordern, Antonia, White, Nancy, Ali, Robert, and Degenhardt, Louisa
- Subjects
- *
OPIOID abuse , *JURISDICTION , *OPIOID analgesics , *DRUG abuse laws , *SUBSTANCE abuse , *INJECTIONS , *INTRAVENOUS drug abuse , *ALCOHOLISM , *ANALGESICS , *DRUG therapy , *INTERVIEWING , *RESEARCH methodology , *META-analysis , *NARCOTICS , *PAIN , *OXYCODONE - Abstract
Introduction and Aims: The harms associated with non-medical use of pharmaceutical opioid analgesics are well established; however, less is known about the characteristics and drug-use patterns of the growing and hidden populations of people using pharmaceutical opioids illicitly, including the frequency of pharmaceutical opioid injection. This paper aimed to undertake a detailed examination of jurisdictional differences in patterns of opioid use among a cohort of people who regularly tamper with pharmaceutical opioids in Australia.Design and Methods: Data were drawn from the National Opioid Medications Abuse Deterrence study. The cohort was recruited from New South Wales (NSW; n = 303), South Australia (SA; n = 150) and Tasmania (TAS; n = 153) to participate in face-to-face structured interviews collecting data on use of pharmaceutical opioids, benzodiazepines, other sedative drugs and illicit substances, as well as the harms associated with substance use.Results: TAS participants reported greater use and injection of certain pharmaceutical opioids (particularly morphine and methadone tablets), and limited heroin use, with lower rates of engagement in opioid substitution treatment, compared with NSW participants. NSW participants were more socially disadvantaged and more likely to report risky injecting behaviours and injecting-related injuries and diseases compared with SA and TAS participants. SA participants reported greater rates of pain conditions, greater use of pain-based services, as well as broader use of pharmaceutical opioids in regards to forms and route of administration, compared with NSW participants.Discussion and Conclusions: Distinct jurisdictional profiles were evident for people who tamper with pharmaceutical opioids, potentially reflecting jurisdictional differences in prescribing regulatory mechanisms and addiction treatment models. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
34. Nutritional intake of opioid replacement therapy patients in community pharmacies: A pilot study.
- Author
-
Waddington, Freya, Naunton, Mark, Kyle, Greg, and Cooper, Gabrielle
- Subjects
- *
ACADEMIC medical centers , *DRUG withdrawal symptoms , *INTERVIEWING , *MINERALS , *NARCOTICS , *NUTRITION , *NUTRITION education , *QUESTIONNAIRES , *VITAMINS - Abstract
Aim: Opioid replacement therapy (ORT) is an established therapy for a patient group that has been associated with nutrition ‐ related comorbidities. This paper aims to assess the nutritional intake and supplementation in ORT patients, determine the extent of nutritional/dietary advice supplied to ORT patients and to briefly examine patients' perception of pharmacists' provision of nutritional advice. Methods: The nutritional intake of ORT patients receiving treatment in community pharmacies within the Australian Capital Territory was assessed via a 24 ‐ hour recall survey. Food intake data were analysed via nutrient analysis software and compared with Australian Nutrition Reference Values and the nutrient intakes of the Australian population. Patients were surveyed to determine supplement use and perceptions of nutritional advice gained by pharmacists. Results: Potential insufficient intake of various macronutrients and micronutrients was observed in both sexes. Less than 25% of patients recorded supplement use. Fifteen percent of males and 21% of females stated that they had approached a pharmacist with a nutrition ‐ related query. All patients who received nutritional advice followed the advice. Conclusions: ORT patients dosing at community pharmacies appear to have poor nutritional intake. ORT patients appear to be receptive to pharmacist's advice. Community pharmacists can potentially increase the beneficial health outcomes in this population through the proactive supply of accurate nutritional advice. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. HIV, opiates, and enteric neuron dysfunction.
- Author
-
Galligan, J. J.
- Subjects
- *
HIV infection risk factors , *NARCOTICS , *NEURONS , *T cells , *CENTRAL nervous system diseases - Abstract
Human immune deficient virus ( HIV) is an immunosuppressive virus that targets CD4+ T-lymphocytes. HIV infections cause increased susceptibility to opportunistic infections and cancer. HIV infection can also alter central nervous system ( CNS) function causing cognitive impairment. HIV does not infect neurons but it does infect astrocytes and microglia in the CNS. HIV can also infect enteric glia initiating an intestinal inflammatory response which causes enteric neural injury and gut dysfunction. Part of the inflammatory response is HIV induced production of proteins including, Transactivator of transcription (Tat) which contribute to neuronal injury after release from HIV infected glial cells. A risk factor for HIV infection is intravenous drug use with contaminated needles and chronic opiate use can exacerbate neural injury in the nervous system. While most research focuses on the actions of Tat and other HIV related proteins and opiates on the brain, recent data indicate that Tat can cause intestinal inflammation and disruption of enteric neuron function, including alteration of Na+ channel activity and action potential generation. A paper published in this issue of Neurogastroenterology and Motility extends these findings by identifying an interaction between Tat and morphine on enteric neuron Na+ channels and on intestinal motility in vivo using a Tat expressing transgenic mouse model. These new data show that Tat protein can enhance the inhibitory actions of morphine on action potential generation and propulsive motility. These findings are important to our understanding of how HIV causes diarrhea in infected patients and for the use of opioid drugs to treat HIV-induced diarrhea. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. The 'misery factor' of withdrawal, instead of the positive reinforce of euphoria, holds keys to new treatments: Koob.
- Subjects
- *
ALCOHOLISM , *BEHAVIOR modification , *CORTICOTROPIN releasing hormone , *DOPAMINE , *DRUG addiction , *EMOTIONS , *INTERPERSONAL relations , *NARCOTICS , *REINFORCEMENT (Psychology) , *REWARD (Psychology) , *POSITIVE psychology - Abstract
A new research paper on the neurobiology of opioid addiction is replete with complex terms, such as the pivotal "hyperkatifeia" (coined about a decade ago to describe an increase in the intensity of the negative emotional signs of drug withdrawal). But the primary takeaway message from the report's author, National Institute on Alcohol Abuse and Alcoholism (NIAAA) Director George Koob, M.D., is much more accessible and direct. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. NA success linked to support by treatment.
- Author
-
Knopf, Alison
- Subjects
- *
MEDICAL referrals , *NARCOTICS , *SUPPORT groups , *SUBSTANCE abuse treatment , *TREATMENT programs - Abstract
A deeply researched white paper shows how mutual support groups can assist — and have assisted — people trying to deal with their drug use. The paper summarizes research on the use of these support groups and details how Narcotics Anonymous (NA) helps drug users, in much the same way Alcoholics Anonymous helps alcohol users, but there are some important distinctions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Beacon calls for primary care and MAT to expand opioid treatment access.
- Author
-
Knopf, Alison
- Subjects
- *
BUPRENORPHINE , *CHRONIC diseases , *CONTINUUM of care , *HEALTH services accessibility , *INSURANCE companies , *MANAGED care programs , *MEDICAL care , *NARCOTICS , *PRIMARY health care , *SUBSTANCE abuse treatment , *HEALTH insurance reimbursement - Abstract
The article discusses a white paper issued by Beacon Health Options "Confronting the Crisis of Opioid Addication" calling for a focus on outpatient medication-assisted treatment by primary care. Topics discussed include its focus on the need to treat opioid addiction as chronic condition, its criticism of providers of detox who did not participate in the continuum of care needed for chronic conditions and its support for 10 levels of care of the American Society of Addiction Medicine (ASAM).
- Published
- 2015
- Full Text
- View/download PDF
39. Self-limiting non-medical pharmaceutical opioid use among young people in Sydney, Australia: An exploratory study.
- Author
-
Dertadian, George C., Dixon, Thomas C., Iversen, Jennifer, and Maher, Lisa
- Subjects
- *
OPIOIDS , *HIV prevention , *DEMOGRAPHIC surveys , *DATA , *DRUG therapy , *SUBSTANCE abuse & psychology , *ANALGESICS , *LEARNING , *NARCOTICS , *ORAL drug administration , *SOCIAL classes , *SUBSTANCE abuse , *PSYCHOLOGY - Abstract
Introduction and Aims: Indicators suggest an escalation in opioid use globally, with recent HIV outbreaks linked to non-medical pharmaceutical opioid (NMPO) use. Little is known about how young Australians engage in NMPO use.Design and Methods: During 2015, we conducted qualitative interviews with young people (16-29 years) who reported oral NMPO use at least twice in the past 90 days. The study included a sample of injecting (n = 14) and oral (n = 22) users. This paper focuses on the oral user group.Results: Most participants grew up in affluent areas of Sydney, reported few health problems, rarely accessed health or welfare services and had limited contact with police. NMPO use was part of a repertoire of drug use involving: (i) use to come down from stimulants; (ii) use in conjunction with cannabis and alcohol; and (iii) use by itself. Participants reported limiting their use in order to avoid stigma and dependence.Discussion and Conclusions: Results suggest culture of self-limiting NMPO use characterised by stable housing, disposable income and intimate friendship networks. Despite the adverse health outcomes observed in other settings, our data suggest that the patterns and meanings of NMPO use observed in this small sample may help explain the limited nature of problematic use among young Australians to date. Findings indicate a need for epidemiological data, including longitudinal data, to assess possible demographic shifts in NMPO use in Australia, and to address risk factors for dependence and transitions to injecting and heroin use in this population. [Dertadian GC, Dixon TC, Iversen J, Maher L. Self-limiting non-medical pharmaceutical opioid use among young people in Sydney, Australia: An exploratory study. Drug Alcohol Rev 2017;00:000-000]. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.